Literature DB >> 17046437

Pathophysiology and treatment of hypertrophic cardiomyopathy.

Mark V Sherrid1.   

Abstract

All patients with hypertrophic cardiomyopathy (HCM) should have five aspects of care addressed. An attempt should be made to detect the presence or absence of risk factors for sudden arrhythmic death. If the patient appears to be at high risk, discussion of the benefits and risks of ICD are indicated, and many such patients will be implanted. Symptoms are appraised and treated. Bacterial endocarditis prophylaxis is recommended. Patients are advised to avoid athletic competition and extremes of physical exertion. First degree family members should be screened with echocardiography and ECG.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17046437     DOI: 10.1016/j.pcad.2006.08.001

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  10 in total

Review 1.  Indications for implantable cardioverter defibrillator use for primary prevention of sudden cardiac death.

Authors:  Mithilesh K Das; Rajdeep Gaitonde; John M Miller
Journal:  Curr Cardiol Rep       Date:  2007-09       Impact factor: 2.931

2.  Effects of exercise on the duration of diastole and on interventricular phase differences in patients with hypertrophic cardiomyopathy: relationship to cardiac output reserve.

Authors:  Gunnar Plehn; Julia Vormbrock; Axel Meissner; Hans-Joachim Trappe
Journal:  J Nucl Cardiol       Date:  2009-01-22       Impact factor: 5.952

Review 3.  Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Marios Matiakis; Hannes Melnyk; Sophie Mavrogeni; Dionyssios Leftheriotis; Boris Bigalke; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

Review 4.  Fluid dynamic aspects of ejection in hypertrophic cardiomyopathy.

Authors:  Ares Pasipoularides
Journal:  Hellenic J Cardiol       Date:  2011 Sep-Oct

5.  Dual chamber pacing relieves obstruction in Japanese-variant hypertrophic cardiomyopathy.

Authors:  Omar Wever-Pinzon; Jorge Romero; Juan P Cordova
Journal:  Am J Ther       Date:  2013 Sep-Oct       Impact factor: 2.688

Review 6.  Hypertrophic Obstructive Cardiomyopathy.

Authors:  Angelika Batzner; Hans-Joachim Schäfers; Konstantin V Borisov; Hubert Seggewiß
Journal:  Dtsch Arztebl Int       Date:  2019-01-25       Impact factor: 5.594

7.  Solution structure of human cardiac troponin C in complex with the green tea polyphenol, (-)-epigallocatechin 3-gallate.

Authors:  Ian M Robertson; Monica X Li; Brian D Sykes
Journal:  J Biol Chem       Date:  2009-06-20       Impact factor: 5.157

8.  A Case of an Acutely Ill Adult Athlete with Previously Undiagnosed Hypertrophic Obstructive Cardiomyopathy.

Authors:  Michael R Minckler; Madeleine Maker
Journal:  Cureus       Date:  2019-06-10

Review 9.  Preintervention imaging and intraoperative management care of the hypertrophic obstructive cardiomyopathy patient.

Authors:  Jacobo Moreno Garijo; Cristina Ibáñez; Juan M Perdomo; Martin D Abel; Massimiliano Meineri
Journal:  Asian Cardiovasc Thorac Ann       Date:  2021-09-24

10.  Mechanical aberrations in hypetrophic cardiomyopathy: emerging concepts.

Authors:  Dimitrios Ntelios; Georgios Tzimagiorgis; Georgios K Efthimiadis; Haralambos Karvounis
Journal:  Front Physiol       Date:  2015-08-19       Impact factor: 4.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.